The overall goal of this Program Project is to improve the outcome of allogeneic bone marrow transplantation (BMT) in the treatment of hematologic malignancies. General topics which will be addressed by this Program Project include the eradication of malignancy, expansion of the donor pool, and the development of methods to diminish or prevent transplant-related complications. Eleven individual research projects are proposed which will work collaboratively on these topics: 1. Treatment of patients with myeloid malignancies with BMT from HLA- identical family members. 2. Treatment of patients with lymphoid malignancies with BMT from HLA- identical family members. 3. Alternative marrow donors for patients lacking an HLA-identical family member. 4. Prevention and treatment of graft-versus-host disease. 5. Virus-mediated myelosuppression. 6. Hematopoietic growth factors in BMT. 7. Detection of minimal residual disease. 8. Pathophysiology and prevention of multiorgan failure after BMT. 9. Prevention and treatment of infection. 10. Specific adoptive immunotherapy of human disease with T-cell clones. 11. Induction or amplification of a graft-versus-leukemia effect by lymphokines and lymphocytes. Our ability to carry out the studies proposed in this Program Project is enhanced by: 1) preclinical research programs which focus on murine or canine models and allow rapid and logical translation of preclinical concepts to phase I clinical trials, 2) the accrual of on average 325 allogeneic transplant patients onto research studies each year, 3) supportive care programs in biostatistics, pathology, microbiology, pharmacology, transfusion care, critical care, gastroenterology, oral medicine, nutrition, social services, long-term follow-up and administration, and 4) our unique structure as a large group of investigators all of whom are focused on the general topic of BMT. Success in the achievement of the goal of this Program Project will likely have relevance for the use of other intensive therapies to treat hematologic malignancies, for the wider application of transplantation in the treatment of other malignant, and nonmalignant diseases and for the care of immunocompromised patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-19
Application #
2086658
Study Section
Special Emphasis Panel (SRC (C1))
Project Start
1978-12-01
Project End
1996-11-30
Budget Start
1994-02-04
Budget End
1994-11-30
Support Year
19
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications